利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

5 条记录 (耗时 0.01 秒)

    ANTITUMOR AGENTS
    4.
    发明授权
    ANTITUMOR AGENTS 有权
    抗肿瘤MEDIUM

    公开(公告)号：EP1407784B1

    公开(公告)日：2010-11-24

    申请号：EP02738789.3

    申请日：2002-06-24

    申请人： Ajinomoto Co., Inc.

    发明人： NIHEI, Yukio ,  MORINAGA, Yoshihiro ,  SUZUKI, Manabu ,  SUGA, Yasuyo

    IPC分类号： A61K31/05 ,  A61K31/167 ,  A61K31/573 ,  A61K45/06 ,  A61P35/00

    CPC分类号： A61K31/05 ,  A61K31/167 ,  A61K31/573 ,  A61K45/06 ,  A61K2300/00

    摘要： Antitumor agents with a combined use of a tublin polymerization inhibitor having an antitumor activity with an antiinflammatory agent. These two active ingredients may be contained in a single preparation. Alternatively, two preparations containing the respective ingredients to be administered separately may be combined with each other. In case of using a tublin polymerization inhibitor as the active ingredient of an antitumor agent, the toxicity of the tublin polymerization inhibitor at the pharmaceutically effective dose can be largely relieved while maintaining the pharmaceutically effective dose and the fatal dose can be increased to thereby broaden the safety range. Moreover, antitumor methods (treatment methods for the treatment, improvement, inhibition of progress, prevention, etc. of tumor in vivo), use of the above two active ingredients in drugs such as antitumor agents, and combined use of the above two active ingredients as drugs such as antitumor agents either simultaneously or separately.

    ANTITUMOR AGENTS
    5.
    发明公开
    ANTITUMOR AGENTS 有权
    ANTITUMORALE MITTEL

    公开(公告)号：EP1407784A1

    公开(公告)日：2004-04-14

    申请号：EP02738789.3

    申请日：2002-06-24

    申请人： Ajinomoto Co., Inc.

    发明人： NIHEI, Yukio ,  MORINAGA, Yoshihiro ,  SUZUKI, Manabu ,  SUGA, Yasuyo

    IPC分类号： A61K45/08 ,  A61P35/00

    CPC分类号： A61K31/05 ,  A61K31/167 ,  A61K31/573 ,  A61K45/06 ,  A61K2300/00

    摘要： An anti-tumor agent comprises a tubulin polymerization-inhibitory active substance having anti-tumor activity and an anti-inflammatory active substance (in combination; in combined use) is made. Both the effective components can be contained in a single pharmaceutical,or can be combined in the form of separately administered 2 kinds of pharmaceuticals.
    In the use of a tubulin polymerization-inhibitory active substance as an effective component in an anti-tumor agent, the anti-tumor agent can maintain its pharmaceutically effective dosage, but at the same time can significantly increase the lethal dosage and improve toxicity at the pharmaceutically effective dosage of the tubulin polymerization inhibitory active substance.

    摘要翻译： 新的抗肿瘤剂（A）包括：（1）具有抗肿瘤活性的吐温聚合抑制剂（I） 和（2）任选组合使用的抗炎剂（II）。 还包括用于治疗肿瘤的方法的独立权利要求，其包括向体内施用（A）。 活动：细胞抑制 抗炎; 免疫抑制。 （Z）-N- [2-甲氧基-5- [2-（3,4,5-三甲氧基苯基）乙烯基]苯基] -L-丝氨酰胺盐酸盐和地塞米松分别给予恶性肿瘤移植大鼠， 研究并确定了抗肿瘤作用。 没有进一步资料。 作用机制：都柏林聚合抑制剂。